Cancer-related cachexia and oxidative stress: beyond current therapeutic options.

Abstract:

:Cancer-related anorexia/cachexia syndrome is a complex phenomenon in which metabolic abnormalities, proinflammatory cytokines produced by the host immune system, circulating tumor-derived catabolic factors, decreased food intake and probably additional unknown factors all play different roles. This review examines the mechanisms of cancer-related anorexia/cachexia syndrome and the mainstays of its management. The two major options for pharmacological therapy have been progestational agents and corticosteroids. Agents currently under investigation are nonsteroidal anti-inflammatory drugs, N-3 fatty acids, branched-chain amino acids and thalidomide. On the basis of several previously published studies and clinical experience, an innovative treatment approach, which consists of an integrated nutritional and pharmacological treatment, has been developed. This approach, based upon multiple components each targeted at different factors involved, may be effective in both improving objective clinical symptoms, such as lean body mass, and subjective symptoms such as quality of life. A Phase II study has been initiated and Phase III study designed.

authors

Mantovani G,Macciò A,Madeddu C,Massa E

doi

10.1586/14737140.3.3.381

keywords:

subject

Has Abstract

pub_date

2003-06-01 00:00:00

pages

381-92

issue

3

eissn

1473-7140

issn

1744-8328

pii

ERA030312

journal_volume

3

pub_type

杂志文章,评审
  • Antineoplastic therapy-induced pulmonary toxicity.

    abstract::Pulmonary complications of antineoplastic therapy are common and are an important cause of respiratory morbidity. The pulmonary toxicity should be taken into account in every patient with respiratory problems who is or has been treated with antineoplastic agents. The diagnosis of drug-induced pulmonary toxicity is com...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.2013.817684

    authors: Sadowska AM,Specenier P,Germonpre P,Peeters M

    更新日期:2013-08-01 00:00:00

  • Early recurrence risk: aromatase inhibitors versus tamoxifen.

    abstract::Aromatase inhibitors (AIs) are becoming the hormonal treatment of choice for postmenopausal women with early breast cancer. Large, well-controlled clinical studies have established the efficacy and safety of initial adjuvant therapy with letrozole or anastrozole versus the previous standard of 5 years of adjuvant tamo...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/era.10.54

    authors: Bria E,Carlini P,Cuppone F,Vaccaro V,Milella M,Cognetti F

    更新日期:2010-08-01 00:00:00

  • Development of antiangiogenic agents for ovarian cancer.

    abstract::Epithelial ovarian cancer (EOC) remains a major source of cancer morbidity and mortality, despite advances in surgical and chemotherapeutic management. The molecular pathways that control angiogenesis have been demonstrated to be key to the pathogenesis of EOC, and have been shown to have prognostic significance. Incr...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.8.1.21

    authors: Collinson FJ,Hall GD,Perren TJ,Jayson GC

    更新日期:2008-01-01 00:00:00

  • Chemoprevention of prostate cancer.

    abstract::Dietary factors and other naturally occurring substances may emerge as potent therapeutic or preventative agents in the battle against prostate cancer. Much of the current support for these agents is epidemiologically based, but new prospective studies are now underway which may support their use in conventional medic...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.3.2.203

    authors: Ward JF,Blute ML

    更新日期:2003-04-01 00:00:00

  • The LUX-Lung clinical trial program of afatinib for non-small-cell lung cancer.

    abstract::Epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer (NSCLC) represents a distinct disease entity whose molecular phenotype predicts exquisite sensitivity to the reversible EGFR-tyrosine kinase inhibitors (TKIs) gefitinib or erlotinib. However, primary or acquired resistance to these agents remain...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1586/era.11.34

    authors: Metro G,Crinò L

    更新日期:2011-05-01 00:00:00

  • The role of stereotactic body radiotherapy and stereotactic radiosurgery in the re-irradiation of metastatic spinal tumors.

    abstract::Stereotactic body radiotherapy (SBRT) and stereotactic radiosurgery (SRS) are advanced radiotherapy delivery techniques that allow for the delivery of high-dose per fraction radiation. Advances in imaging technology and intensity modulation have allowed SRS and SBRT to be used for the treatment of tumors in close prox...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.2014.940326

    authors: Jain AK,Yamada YJ

    更新日期:2014-10-01 00:00:00

  • Optimal treatment of metastatic colorectal cancer.

    abstract::For over 40 years, fluorouracil has been the only drug registered for the treatment of metastatic colorectal cancer. During the past 5 years, combination chemotherapy regimens including either irinotecan or oxaliplatin have proven to be superior to fluorouracil monotherapy in randomized clinical trials, in terms of re...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.6.5.801

    authors: Pessino A,Sobrero A

    更新日期:2006-05-01 00:00:00

  • Health-related quality of life in cancer patients treated with PD-(L)1 inhibitors: a systematic review.

    abstract:INTRODUCTION:A systematic review was performed to explore the health-related quality of life (HRQoL) outcomes among cancer patients receiving PD-(L)1 inhibitors compared to those receiving traditional cytotoxic therapy. Areas covered: Citations from PubMed and the American Society of Clinical Oncology meeting library w...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章

    doi:10.1080/14737140.2018.1528146

    authors: Abdel-Rahman O,Oweira H,Giryes A

    更新日期:2018-12-01 00:00:00

  • Metastases of colorectal cancer to the liver and peritoneum: comparison of surgical paradigms.

    abstract::The treatment of metastatic colorectal cancer is evolving. Although the advent of new chemotherapeutic and biologic agents has certainly improved the outlook for many patients, surgical resection in certain subsets of patients with advanced colorectal cancer is the only chance for long-term survival. Traditionally, pa...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.8.11.1797

    authors: Shen P,Stewart JH,Levine EA

    更新日期:2008-11-01 00:00:00

  • Biography: Dr Iain Frame, director of research, prostate cancer UK.

    abstract::Sophia Maprayil, Commissioning Editor for Expert Review of Anticancer Therapy, talks to Dr Iain Frame, Director of Research for Prostate Cancer UK. Iain is Prostate Cancer UK's first Director of Research, responsible for overseeing the development and implementation of the charity's ambitious new research strategy. He...

    journal_title:Expert review of anticancer therapy

    pub_type: 面试

    doi:10.1586/14737140.2014.974898

    authors: Frame I,Maprayil S

    更新日期:2014-11-01 00:00:00

  • Treatment of childhood acute myeloid leukemia.

    abstract::Childhood acute myeloid leukemia is rare, but accounts for a significant number of malignancy-related deaths in this age group. However, the prognosis has improved over past decades, and survival rates of 60% and above have been reported. Still, this implies that more than a third of children and adolescents die from ...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.5.5.917

    authors: ter Bals E,Kaspers GJ

    更新日期:2005-10-01 00:00:00

  • Emerging personalized approaches for the management of advanced urothelial carcinoma.

    abstract::Urothelial carcinoma of the bladder comprises a spectrum of illnesses ranging from nonmuscle-invasive to muscle-invasive to advanced/metastatic disease. Each of these clinical states is characterized by a unique pathogenesis, prognosis and approach to treatment. However, given the heterogeneity of urothelial carcinoma...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/era.12.141

    authors: Tsao CK,Gartrell BA,Oh WK,Galsky MD

    更新日期:2012-12-01 00:00:00

  • Medical approaches to non-melanoma skin cancer.

    abstract::Medical therapy represents an alternative treatment approach that can be considered for some forms of non-melanoma skin cancer (NMSC). In selected cases, topical treatments are preferable to invasive procedures, especially in the case of multifocal lesions, unclear lesion edges, risk of keloids, surgical risk factors ...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.2013.856759

    authors: Micali G,Lacarrubba F,Bhatt K,Nasca MR

    更新日期:2013-12-01 00:00:00

  • Unnatural killer cells to prevent bloodborne metastasis: inspiration from biology and engineering.

    abstract::Metastasis contributes to over 90% of cancer-related deaths. Many types of cancer metastasize via the bloodstream, where circulating tumor cells (CTCs) originating from the primary tumor can undergo selectin-mediated adhesion with the blood vessel wall and subsequently transmigrate to anatomically distant organs. In a...

    journal_title:Expert review of anticancer therapy

    pub_type: 社论

    doi:10.1586/14737140.2014.916619

    authors: Mitchell MJ,King MR

    更新日期:2014-06-01 00:00:00

  • Sequencing therapy in advanced prostate cancer: focus on sipuleucel-T.

    abstract::Immunotherapies such as sipuleucel-T present new and unique challenges for the optimal timing and sequencing of therapies for metastatic castration-resistant prostate cancer (mCRPC). Key considerations for the sequencing of sipuleucel-T are its unique proposed mechanism of action, the time required to generate a clini...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.2014.848065

    authors: Quinn DI,Vaishampayan U,Higano CS,Lin DW,Shore ND,Beer TM

    更新日期:2014-01-01 00:00:00

  • Sentinel lymph node biopsy for melanoma of the head and neck.

    abstract::Since its first description nearly two centuries ago, melanoma has been a difficult disease to diagnose and treat. With the incidence and mortality rates slowly increasing, understanding this disease is more important than ever. Herein, the current diagnostic and treatment recommendations for melanoma of the head and ...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.3.5.673

    authors: Lentsch EJ,McMasters KM

    更新日期:2003-10-01 00:00:00

  • Chronic tyrosine kinase inhibitor (TKI) use in metastatic renal cell carcinoma (mRCC): can this lead to the adverse effect of hypogonadism?

    abstract::Background: Patients with metastatic renal cell carcinoma (mRCC) are commonly treated with tyrosine kinase inhibitors (TKIs). An adverse effect frequently suffered by patients is lethargy, which often leads to dose reduction or drug cessation. We aimed to assess whether hypogonadism is related to treatment with TKIs. ...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章

    doi:10.1080/14737140.2019.1609355

    authors: Afshar M,Patel HRH,Jain A,Kumar A,Patel P,James ND,Porfiri E

    更新日期:2019-06-01 00:00:00

  • Specific challenges in the management of subungual melanoma.

    abstract::Subungual melanoma (SUM) is infrequent in the general population, accounting for 0.7-3.5% of all cutaneous melanomas. SUM absolute incidence is similar among different racial groups; however, the relative proportion among overall cutaneous melanoma cases within each population varies in relation to the frequency of su...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/era.10.216

    authors: De Giorgi V,Saggini A,Grazzini M,Gori A,Rossari S,Scarfì F,Verdelli A,Chimenti S,Lotti T,Massi D

    更新日期:2011-05-01 00:00:00

  • Review of management issues in relapsed osteosarcoma.

    abstract::Osteosarcoma is the most common primary malignant bone tumor in children and adolescents. With combined modality treatment long-term survival rate for localized disease is near 70%. Thirty percent of patients relapse with lung as the commonest site. Surgery is the treatment of choice for relapsed patients whenever pos...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.2014.863453

    authors: Vijayamurugan N,Bakhshi S

    更新日期:2014-02-01 00:00:00

  • Surgical management of bladder cancer in 2003.

    abstract::Recent advances in molecular and cell biology have led to a greater understanding of the basic biology of bladder cancer. However, despite these advances, surgery remains a key component of modern bladder cancer treatment. Endoscopy is the mainstay of the diagnosis and treatment of superficial bladder cancer. Adjuvant...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.3.6.781

    authors: Wade M,Seigne JD

    更新日期:2003-12-01 00:00:00

  • miRNA as markers for the diagnostic screening of colon cancer.

    abstract::Early screening for colon cancer (CC) allows for early stage diagnosis of the malignancy and potentially reduces disease mortality as the cancer is most likely curable at its earliest stages. Early detection would be desirable if accurate, practical and cost-effective diagnostic measures for this cancer were available...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.2014.869479

    authors: Ahmed FE

    更新日期:2014-04-01 00:00:00

  • Implication of miRNA in the diagnosis and treatment of breast cancer.

    abstract::Breast cancer (BC) comprises a group of different diseases characterized by changes in tissue structure and gene expression. Recent advances in molecular biology have shed new light on the participation of genes and their products in the biology of BC. MicroRNAs (miRNAs) are small noncoding endogenous RNA molecules th...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/era.11.40

    authors: Castañeda CA,Agullo-Ortuño MT,Fresno Vara JA,Cortes-Funes H,Gomez HL,Ciruelos E

    更新日期:2011-08-01 00:00:00

  • Current concepts and future strategies in the management of intracranial germinoma.

    abstract::Radiation therapy is the backbone in the management of intracranial germinoma. In localized disease chemotherapy followed by whole brain irradiation is the present standard providing cure rates in excess of 90%. Craniospinal irradiation alone in metastatic disease provides equally excellent outcome. Chemotherapy is ab...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.2014.856268

    authors: Kortmann RD

    更新日期:2014-01-01 00:00:00

  • Cancer of the nasal cavity and paranasal sinuses.

    abstract::Sinonasal malignancies continue to have poor survival rates. Disease-related mortality is usually the result of disease recurrence and progression at the primary site despite aggressive therapy. Complete surgical excision with postoperative radiation therapy remains the standard of care for resectable lesions. Improve...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.4.3.411

    authors: Maghami E,Kraus DH

    更新日期:2004-06-01 00:00:00

  • Olaparib for the treatment of breast cancer.

    abstract:INTRODUCTION:Mutations in BRCA1 and BRCA2 genes account for around 2-3% of breast cancer events and more than 10% of triple negative breast cancers. Olaparib (Lynparza®), an orally administered PARP inhibitor, demonstrated clinical benefit in a phase III trial for mutated BRCA-positive HER2 negative metastatic breast c...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1080/14737140.2018.1458613

    authors: Griguolo G,Dieci MV,Guarneri V,Conte P

    更新日期:2018-06-01 00:00:00

  • Prostate-sparing cystectomy: has Pandora's box been opened?

    abstract::En bloc removal of the prostate has traditionally been an integral component of radical cystectomy for men with bladder cancer owing to a high incidence of occult prostatic malignancy. However, the risk of functional morbidity following this procedure is considerable and can delay patient acceptance of cystectomy, whi...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.7.7.1003

    authors: Kefer JC,Cherullo EE,Jones JS,Gong MC,Campbell SC

    更新日期:2007-07-01 00:00:00

  • MUC1 induces tamoxifen resistance in estrogen receptor-positive breast cancer.

    abstract:INTRODUCTION:Tamoxifen, as an essential therapeutic tool in the treatment of estrogen receptor-positive breast cancer, has been available for the past three decades and is currently being utilized as a chemo-preventive agent for patients at high risk for breast carcinoma. However, the induction of chemo-resistance duri...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1080/14737140.2017.1340837

    authors: Merikhian P,Ghadirian R,Farahmand L,Mansouri S,Majidzadeh-A K

    更新日期:2017-07-01 00:00:00

  • CyberKnife robotic radiosurgery system for tumor treatment.

    abstract::Defined by its high level of accuracy and rapid radiation dose fall-off, radiosurgery has emerged as an effective radiation technique over the past few decades. Although it was once limited to conditions of the brain, head and neck regions, technological advances in computing and imaging have allowed the application o...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.7.11.1507

    authors: Hara W,Soltys SG,Gibbs IC

    更新日期:2007-11-01 00:00:00

  • A catalogue of treatment and technologies for malignant pleural mesothelioma.

    abstract::Malignant pleural mesothelioma is an aggressive fatal malignancy with a prognosis that has not significantly improved in the last decades. This review summarizes the current state of treatment and the various attempts that are made to improve overall survival for patients with malignant pleural mesothelioma. It also d...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.2016.1162100

    authors: Schunselaar LM,Quispel-Janssen JM,Neefjes JJ,Baas P

    更新日期:2016-01-01 00:00:00

  • Benefits of laparoscopic prostate-sparing radical cystectomy.

    abstract:PURPOSE:Prostate-sparing radical cystectomy has been described in the literature and has proven to be a promising procedure owing to the continence and erectile function results without necessarily compromising the oncologic outcome in selected patients. TECHNIQUE POINTS:A transperitoneal approach is used. Lymph node ...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.6.1.21

    authors: Rozet F,Harmon J,Arroyo C,Cathelineau X,Barret E,Vallancien G

    更新日期:2006-01-01 00:00:00